Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1Expanded_access 1

Sponsor

Cancer Type

CNS 1

Conditions

Glioma 3Astrocytoma 3Brain Neoplasms 2Oligodendroglioma 1Lymphoma, Follicular 1Healthy Adult Participants 1

Interventions

Temozolomide 73Radiotherapy 33Carboplatin 21Bevacizumab 18Irinotecan 16Carmustine 16Magnetic Resonance Spectroscopy 15Vincristine 14Surgical Procedures, Operative 13Filgrastim 13Procarbazine 10Erlotinib Hydrochloride 8Cyclophosphamide 8Peripheral Blood Stem Cell Transplantation 7O(6)-benzylguanine 7Lomustine 7Etoposide 7sargramostim 6Imatinib Mesylate 6Flucytosine 6Cisplatin 62-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole 6temsirolimus 5Vorinostat 5Thiotepa 5Radiotherapy, Intensity-Modulated 5Radiation 5Biopsy 52,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide 5vocimagene amiretrorepvec 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Oligodendroglioma × vorasidenib × Clear all
NCT05484622 2026-03-12

Study of Vorasidenib and Pembrolizumab Combination in Recurrent or Progressive IDH-1 Mutant Glioma

Servier

Phase 1 Active not recruiting
60 enrolled
CNS

Astrocytoma, Oligodendroglioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡